Stifel resumed coverage of Rhythm Pharmaceuticals (NASDAQ:RYTM) with a “buy” rating and $23 price target. The stock closed at $8.49 on March 1. Rhythm is a commercial biopharmaceutical company developing therapeutics...
In its biotech outlook, Stifel said that “on heels of weakness and negativity, 2022 may turn out to be a rebound year wherein biotech stocks – particularly decliners despite positive results and/or commercial...
Stifel launched coverage of Surrozen (NASDAQ:SRZN) with a “buy” rating and $19 target price. The stock closed at $7.24 on Sept. 3. Surrozen discovers and develops biologic drug candidates to selectively modulate the Wnt...
Stifel upgraded ChemoCentryx (NASDAQ:CCXI) to “buy” from “hold” and raised its price target to $31 from $26, citing a more favorable risk/reward for avacopan heading into a new PDUFA date. The stock closed at $14.05 on...
Stifel initiated coverage of ProQR Therapeutics N.V. (NASDAQ:PRQP) with a “buy” rating and price target of $20. The stock finished at $6.22 on April 30. “As a clinical-stage company with demonstrated proof-of-concept...
Stifel began coverage on 10 rare disease-focused companies, with seven “buy” and three “hold” ratings, noting that with an estimated 7,000-plus rare diseases – 95% of which lack approved therapy – these are early...